MiNK Therapeutics' Q1 net loss narrows slightly

MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc.

INKT

0.00


Overview

  • US cell therapy developer posted Q1 net loss of $2.7 mln, slightly narrower yr/yr

  • Company ended Q1 with $9.5 mln in cash, after repaying $5.2 mln note and raising $3 mln


Result Drivers

  • NON-DILUTIVE COLLABORATIONS - Selective collaborations provided external funding to support pipeline expansion while preserving focus on lead programs

  • DISCIPLINED SPENDING - Company emphasized reduced operating burn and focused advancement of high-priority programs


Company press release: ID:nGNX9mTf3t


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 EPS

-$0.57

Q1 Net Income

-$2.70 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Mink Therapeutics Inc is $39.00, about 271.1% above its May 14 closing price of $10.51


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.